

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/034313 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) *A61K 31/444* (2006.01)
C07F 1/08 (2006.01) *A61K 31/4725* (2006.01)
C07F 3/06 (2006.01) *A61K 31/555* (2006.01)
C07F 13/00 (2006.01)

(21) International Application Number:

PCT/GB2021/052070

(22) International Filing Date:

10 August 2021 (10.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2012482.2 11 August 2020 (11.08.2020) GB

(71) Applicant: UNIVERSITY OF HUDDERSFIELD


[GB/GB]; Queensgate, Huddersfield Yorkshire HD1 3DH (GB).

(72) Inventors: **ALLISON, Simon John**; School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH (GB). **PHILLIPS, Roger Mortimer**; School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH (GB). **RICE, Craig Raymond**; School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH (GB).

(74) Agent: **HGF LIMITED**; Document Handling - HGF (Manchester), 1 City Walk, LEEDS Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF



(57) Abstract: The present invention relates to compounds of Formula I: wherein R^1 , L^1 , A, X^a , L^2 , B and X^b are each as defined herein. The present invention also relates to compounds of Formula II and III defined herein, formed by self-assembly of the compounds of Formula I with a metal M and an anion Q. Compounds of Formula II and III are useful in the treatment of proliferative disorders, such as cancer. The present invention also relates to pharmaceutical compositions comprising compounds of Formula I, II or III, and to the use of these compounds and compositions in the treatment of proliferative disorders, such as cancer.

[Continued on next page]



WO 2022/034313 A1

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*